Bicycle Therapeutics Plc Share Price Today
(NASDAQ: BCYC)

Name: Bicycle Therapeutics Plc Share Price Today (NASDAQ: BCYC) - Bicycle Therapeutics Plc Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Bicycle Therapeutics Plc share price is $10.38 & ₹902.74 as on 6 Mar 2025, 2.30 'hrs' IST

$10.38

▲

0.24

(2.37%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Bicycle Therapeutics Plc share price in Dollar and Rupees. Guide to invest in Bicycle Therapeutics Plc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Bicycle Therapeutics Plc, along with analyst recommendations, forecasts, and comprehensive financials.

Bicycle Therapeutics Plc share price movements

Today's Low: $10.00
Today's High: $10.62
$10.38
3.71%
Downside
Day's Volatility :5.84%
Upside
2.21%
52 Weeks Low: $10.12
52 Weeks High: $28.67
$10.38
2.5%
Downside
52 Weeks Volatility :64.7%
Upside
63.8%

Bicycle Therapeutics Plc (BCYC) Returns

Period	Bicycle Therapeutics Plc	Sector (Health Care)	Index (Russel 2000)
3 Months	-47.21%	2.1%	0.0%
6 Months	-50.37%	-4.1%	0.0%
1 Year	-58.85%	2.2%	0.0%
3 Years	-75.9%	11.8%	-11.6%

Bicycle Therapeutics Plc (BCYC) Key Statistics

in dollars & INR

Previous Close	$10.14
Open	$10.15
Today's High	$10.615
Today's Low	$9.995
Market Capitalization	$776.8M
Today's Volume	$127.3K
52 Week High	$28.670102
52 Week Low	$9.995
Revenue TTM	$36.9M
EBITDA	$-189.3M
Earnings Per Share (EPS)	$-3.28
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-26.67%

How to invest in Bicycle Therapeutics Plc Stock (BCYC) from India?

It is very easy for Indian residents to invest directly in Bicycle Therapeutics Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Bicycle Therapeutics Plc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Bicycle Therapeutics Plc or BCYC on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Bicycle Therapeutics Plc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Bicycle Therapeutics Plc shares which would translate to 0.084 fractional shares of Bicycle Therapeutics Plc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Bicycle Therapeutics Plc, in just a few clicks!

Returns in Bicycle Therapeutics Plc (BCYC) for Indian investors in Rupees

The Bicycle Therapeutics Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Bicycle Therapeutics Plc investment value today

Current value as on today

₹47,089

Returns

₹52,911

(-52.91%)

Returns from Bicycle Therapeutics Plc Stock

₹57,873 (-57.87%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Bicycle Therapeutics Plc (BCYC)

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Bicycle Therapeutics Plc Stock from India on INDmoney has increased by 0% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Bicycle Therapeutics Plc

Baker Bros Advisors LP
15.73%
Point72 Asset Management, L.P.
6.58%
FCPM III SERVICES BV
4.99%
Westfield Capital Management Company, L.P.
3.77%
Armistice Capital, LLC
3.17%
Siren, L.L.C.
2.66%

Analyst Recommendation on Bicycle Therapeutics Plc

Buy

88%Buy

11%Hold

0%Sell

Based on 18 Wall street analysts offering stock ratings for Bicycle Therapeutics Plc(by analysts ranked 0 to 5 stars)

Based on 18 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Bicycle Therapeutics Plc Stock (BCYC)

What analysts predicted

Upside of 209.16%

Target:

$32.09

Current:

$10.38

Insights on Bicycle Therapeutics Plc Stock (Ticker Symbol: BCYC)

Price Movement
In the last 3 months, BCYC stock has moved down by -47.2%
Increasing Revenue
Revenue is up for the last 2 quarters, 2.67M → 3.70M (in $), with an average increase of 27.8% per quarter
Decreasing Net Profit
Netprofit is down for the last 4 quarters, -26.54M → -51.85M (in $), with an average decrease of 26.6% per quarter
BCYC vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 121.2%
BCYC vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 124.0%
Price to Sales
ForBCYC every $1 of sales, investors are willing to pay $14.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

BCYC Bicycle Therapeutics Plc Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$13.8M	↑ 93.4%
Net Income	$-30.6M	↑ 40.11%
Net Profit Margin	-221.78%	↑ 84.36%

	FY20	Y/Y Change
Revenue	$10.4M	↓ 24.72%
Net Income	$-51.0M	↑ 66.66%
Net Profit Margin	-490.95%	↓ 269.17%

	FY21	Y/Y Change
Revenue	$11.7M	↑ 12.58%
Net Income	$-66.8M	↑ 30.99%
Net Profit Margin	-571.25%	↓ 80.3%

	FY22	Y/Y Change
Revenue	$14.5M	↑ 23.65%
Net Income	$-112.7M	↑ 68.69%
Net Profit Margin	-779.35%	↓ 208.1%

	FY23	Y/Y Change
Revenue	$27.0M	↑ 86.52%
Net Income	$-180.7M	↑ 60.28%
Net Profit Margin	-669.72%	↑ 109.63%

	FY24	Y/Y Change
Revenue	$35.3M	↑ 30.76%
Net Income	$-169.0M	↓ 6.44%
Net Profit Margin	-479.18%	↑ 190.54%

	Q3 FY23	Q/Q Change
Revenue	$5.4M	↓ 53.04%
Net Income	$-49.9M	↑ 17.12%
Net Profit Margin	-932.32%	↓ 558.51%

	Q4 FY23	Q/Q Change
Revenue	$5.3M	↓ 0.39%
Net Income	$-49.1M	↓ 1.6%
Net Profit Margin	-921.01%	↑ 11.31%

	Q1 FY24	Q/Q Change
Revenue	$19.5M	↑ 266.14%
Net Income	$-26.5M	↓ 45.93%
Net Profit Margin	-136.01%	↑ 785.0%

	Q2 FY24	Q/Q Change
Revenue	$9.4M	↓ 51.99%
Net Income	$-39.9M	↑ 50.13%
Net Profit Margin	-425.3%	↓ 289.29%

	Q3 FY24	Q/Q Change
Revenue	$2.7M	↓ 71.45%
Net Income	$-50.8M	↑ 27.46%
Net Profit Margin	-1.9K%	↓ 1473.13%

	Q4 FY24	Q/Q Change
Revenue	$3.7M	↑ 38.57%
Net Income	$-51.9M	↑ 2.07%
Net Profit Margin	-1.4K%	↑ 499.99%

	FY19	Y/Y Change
Profit	$13.8M	↑ 93.4%

	FY20	Y/Y Change
Profit	$-22.8M	↓ 264.91%

	FY21	Y/Y Change
Profit	$-33.2M	↑ 45.8%

	FY22	Y/Y Change
Profit	$10.8M	↓ 132.48%

	FY23	Y/Y Change
Profit	$20.5M	↑ 90.32%

	FY24	Y/Y Change
Profit	$35.3M	↑ 72.0%

	Q3 FY23	Q/Q Change
Profit	$3.7M	↓ 62.33%

	Q4 FY23	Q/Q Change
Profit	$3.7M	↓ 0.25%

	Q1 FY24	Q/Q Change
Profit	$17.9M	↑ 387.68%

	Q2 FY24	Q/Q Change
Profit	$7.7M	↓ 56.73%

	Q3 FY24	Q/Q Change
Profit	$481.7K	↓ 93.77%

	Q4 FY24	Q/Q Change
Profit	$3.7M	↑ 669.74%

	FY19	Y/Y Change
Operating Cash Flow	$-28.6M	↑ 9.72%
Investing Cash Flow	$-1.6M	↑ 31.11%
Financing Cash Flow	$58.4M	↑ 129.81%

	FY20	Y/Y Change
Operating Cash Flow	$-17.8M	↓ 37.83%
Investing Cash Flow	$-1.2M	↓ 22.83%
Financing Cash Flow	$62.8M	↑ 7.53%

	FY21	Y/Y Change
Operating Cash Flow	$-14.8M	↓ 16.84%
Investing Cash Flow	$-2.0M	↑ 69.17%
Financing Cash Flow	$320.7M	↑ 410.36%

	FY22	Y/Y Change
Operating Cash Flow	$-86.1M	↑ 482.07%
Investing Cash Flow	$-19.0M	↑ 835.32%
Financing Cash Flow	$6.7M	↓ 97.91%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-1.0M	↓ 103.01%
Investing Cash Flow	$-502.0K	↑ 81.23%
Financing Cash Flow	$234.6M	↑ 1808.81%

Bicycle Therapeutics Plc Technicals Summary

Sell

Neutral

Buy

Bicycle Therapeutics Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Bicycle Therapeutics Plc (BCYC) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Bicycle Therapeutics Plc	-19.91%	-50.37%	-58.85%	-75.9%	-31.67%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Bicycle Therapeutics Plc	NA	NA	NA	-3.05	-0.27	-0.15	NA	12.04
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Bicycle Therapeutics Plc	Buy	$776.8M	-31.67%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Bicycle Therapeutics Plc

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Organization	Bicycle Therapeutics Plc
Employees	305
CEO	Dr. Kevin Lee M.B.A., Ph.D.
Industry	Biotechnology

Management People of Bicycle Therapeutics Plc

Name	Title
Dr. Kevin Lee M.B.A., Ph.D.	CEO & Executive Director
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE, Ph.D.	Co-Founder & Non-Executive Director
Ms. Alethia Rene Young	Chief Financial Officer
Dr. Santiago Arroyo M.D., Ph.D.	Chief Development Officer
Dr. Christian Heinis	Scientific Founder
Mr. Alistair Milnes	Chief Operating Officer
Mr. Travis Thompson	Senior VP, Chief Accounting Officer & Principal Accounting Officer
Dr. Michael Skynner B.sc. Ph.d., Ph.D.	Chief Technology Officer
Ms. Stephanie Yao	Senior Vice President of Investor Relations and Corporate Communications
Mr. Zafar Qadir	Chief Legal Officer & General Counsel

Important FAQs about investing in BCYC Stock from India :

What is Bicycle Therapeutics Plc share price today?

Bicycle Therapeutics Plc share price today stands at $10.38, Open: $10.15 ; Previous Close: $10.14 ; High: $10.62 ; Low: $10.00 ; 52 Week High: $28.67 ; 52 Week Low: $10.12.

The stock opens at $10.15, after a previous close of $10.14. The stock reached a daily high of $10.62 and a low of $10.00, with a 52-week high of $28.67 and a 52-week low of $10.12.

Can Indians buy Bicycle Therapeutics Plc shares?

Yes, Indians can invest in the Bicycle Therapeutics Plc (BCYC) from India.

With INDmoney, you can buy Bicycle Therapeutics Plc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Bicycle Therapeutics Plc at zero transaction cost.

How can I buy Bicycle Therapeutics Plc shares from India?

It is very easy to buy Bicycle Therapeutics Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Bicycle Therapeutics Plc (BCYC) be purchased?

Yes, you can buy fractional shares of Bicycle Therapeutics Plc with INDmoney app.

What are the documents required to start investing in Bicycle Therapeutics Plc stocks?

To start investing in Bicycle Therapeutics Plc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.